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Abstract
Sixty cancer cell lines have been extensively characterized and used by the National Cancer
Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools
for anti-cancer drug development. An extensive database has been accumulated that could be used
to select individual cells lines for specific experimental designs based on their global genetic and
biological profile. However, information on the human leukocyte antigen (HLA) genotype of these
cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore,
re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information
may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2)
check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in
which knowledge of HLA molecule expression is relevant. Since genome-based typing does not
guarantee actual surface protein expression, further characterization of relevant cell lines should
be entertained to verify surface expression in experiments requiring correct antigen presentation.
Background
A panel of sixty cancer cell lines of diverse lineage (lung,
renal, colorectal, ovarian, breast, prostate, central nervous
system, melanoma and hematological malignancies) was
developed, characterized and extensively used by the
National Cancer Institute's Developmental Therapeutics
Program (NCI-60) since the early 90's as a screening tool
for anti-cancer drug development [1]. This strategy [2-9].
yielded data about drug-related cytotoxicity for about
100,000 compounds. In addition, extensive functional
characterization of the NCI-60 response to diverse biolog-
ical or chemical stimulation has been accumulated [10-
15]. Although originally developed for chemo-sensitivity
testing, with the development of high-throughput analy-
ses the NCI-60 panel has been broadly characterized for
other biological applications [16-25]. Thus, patterns inci-
dentally identified provided platforms for further investi-
gations of mechanisms of tumorigenesis and cancer
progression [5,6,26-30]. More recently, genomic DNA
[24] and proteomics analyses have further characterized
the profile of these cell lines [31]. The combined database
provides the most comprehensive phenotyping of com-
monly accessible cancer cell lines offering correlative
information about genetic, transcriptional and post-trans-
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Table 1: Available information from the ATCC about the NCI-60 panel
Name ATCC no. Sex Race Tumor Type ATCC HLA typing Discrepant
BT-549 HTB-122 F C Breast CA
HS 578T HTB-126 F C Breast CA
MCF7 HTB-22 F C Breast CA
MDA-MB-231 HTB-26 F C Breast CA
MDA-MB-435 HTB-129 F C Breast CA
T-47D HTB-133 F Breast CA
SF-268 CNS CA
SF-295 CNS CA
SF-539 CNS CA
SNB-19 CNS CA
SNB-75 CNS CA
U251 CNS CA
COLO 205 CCL-222 M C Colon CA
HCC-2998 Colon CA
HCT-116 CCL-247 M Colon CA
HCT-15 CCL-225 M Colon CA
HT29 HTB-38 F C Colon CA A1,3,B12,17 Cw5 Yes
KM12 Colon CA
SW-620 CCL-227 M Colon CA
MOLT-4 CRL-1582 M Leukemia, ALL
CCRF-CEM CCL-119 F C Leukemia, ALL
HL-60 CCL-240 F C Leukemia, APL
K-562 CCL-243 F Leukemia, CML
SR CRL-2262 M C Leukemia, LCIL
LOX IMVI Melanoma
M 14 Melanoma
SK-MEL-2 HTB-68 M C Melanoma
SK-MEL-5 HTB-70 F C Melanoma A2,11, B40,Bw16 Yes
SK-MEL-28 HTB-72 M Melanoma A11,26, B40,DRw4 Yes
UACC-62 Melanoma
UACC-257 Melanoma
RPMI 8226 CCL-155 M MM Aw19, B15,37, Cw2 Yes
A549/ATCC CCL-185 M C NSCLC
EKVX NSCLC
HOP-62 NSCLC
HOP-92 NSCLC
NCI-H23 CRL-5800 M AA NSCLC
NCI-H226 CRL-5826 M NSCLC
NCI-H322M NSCLC
NCI-H460 HTB-177 M NSCLC
NCI-H522 CRL-5810 M C NSCLC
IGROV1 Ovarian CA
OVCAR-3 HTB-161 Ovarian CA
OVCAR-4 Ovarian CA
OVCAR-5 Ovarian CA
OVCAR-8 Ovarian CA
NCI/ADR-RES Ovarian CA
SK-OV-3 HTB-77 F C Ovarian CA
DU-145 HTB-81 M C Prostate CA
PC-3 CRL-1435 M C Prostate CA A1,9 No
786-O Renal CA
A498 HTB-44 F Renal CAJournal of Translational Medicine 2005, 3:11 http://www.translational-medicine.com/content/3/1/11
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lational qualities. With growing interest in the identifica-
tion of novel tumor antigens recognized by T cells as
targets for antigen-specific immunization ([32], the NCI-
60 could become an ideal tool for in silico discovery [33]
([34] and for tumor cell-specific T-cell reactivity testing
[35]. For this purpose, accurate information about the
extended human leukocyte antigen (HLA) phenotype of
each cell line is necessary for the definition and validation
of specific HLA/epitope combinations. Although anti-
quated and partial information about the HLA phenotype
of some of the NCI-60 cell lines is available through the
American Type Culture Collection (ATCC), Rockville,
MD, no high-resolution information obtained by defini-
tive sequence-based typing (SBT) has ever been published.
Since T cell recognition of HLA-epitope complexes is nar-
rowly restricted to unique combinations [36], this infor-
mation is critical to select reasonable candidates for
antigen-discovery choosing cell lines bearing HLA pheno-
types most relevant to the disease population studied
[37]. Accurate information about the HLA genotype of
each cell line may, in addition, help their identification,
validation and qualification among different laboratories
excluding possible errors related to switching of cell lines
or culture contamination. Therefore, we provide high-res-
olution SBT of the complete NCI-60 panel obtained from
their original source: the National Cancer Institute's
Developmental Therapeutics Program.
Results and Discussion
Previous knowledge of the HLA phenotype of NCI-60 cell 
lines
We reviewed and collected available information about
the HLA phenotype of the NCI-60 cell lines, performed
according to serological testing before submission to the
ATCC (Table 1). The information was collected through
the ATCC website: http://www.atcc.org. Most cell lines
had not been previously typed; the large majority of the
cell lines from which such information is available had
been developed from Caucasian patients. HLA typing was
reported according to the old serologic nomenclature at a
very low level of resolution. In addition, several reported
typings did not match the present typing as shown in
Table 2 and 3. This was the case for the colon carcinoma
cell line HT29 that maintained a correct haplotype (with
the exclusion of the HLA-Cw locus) but had a completely
different second haplotype. The melanoma cell line SK-
MEL-5 had an almost identical haplotype with the excep-
tion of one HLA-B allele originally typed as Bw16 (inclu-
sive of the molecularly-defined alleles: B*38 and B*39),
while the present typing was HLA-B*07. Another
melanoma cell line SK-MEL-28 maintained a haplotype
similar to the previously reported HLA-A11, -B40 but
appeared to have lost an HLA-A allele (HLA-A26) com-
pared with the original ATCC description. Finally, the
multiple myeloma cell line RPMI 8226 was matched at
one haplotype (HLA-A19, -B15 and -Cw2) but was totally
discrepant at the second haplotype (HLA-A*6802, -
B*1510 and -Cw*0304). The HLA typing of the other two
previously typed cell lines was confirmed in the present
study. Overall, in spite of the discrepancies in HLA typing
observed between the previous and the present analyses, a
resemblance was noted in the cell line genotype suggest-
ing that mis-typing related to the low accuracy of serolog-
ical methods might have been at the basis of the
discrepancy rather than contamination or switching of the
cell lines.
Overall, there was no evidence of contamination among
the cell lines tested with clean homozygous or hetero-
zygous combinations observed in all loci analyzed. SBT of
HLA class I and HLA class II loci are reported in Table 2
and 3 respectively. Information about the HLA typing of
the cell lines is also available through the Molecular Tar-
gets URL: http://dtp.nci.nih.gov/mtargets/mt_index.html.
Approximately 17% of the cell lines (10 out of 58 includ-
ing: T47D, SNB-19, U251, KM12, RPMI-8226, EKVX,
NCI-H23, NCI-H322M, A498, ACHN and TK-10) exhib-
ited a pseudo-homozygous pattern suggestive of complete
loss of heterozygosity encompassing the HLA class I and
HLA class II regions. This frequency is close to the loss of
ACHN CRL-1611 M C Renal CA
CAK1-1 HTB-46 M C Renal CA A9,B12,35 No
SN12C Renal CA
TK-10 Renal CA
UO-31 Renal CA
RXF-393 Renal CA
AA = African American; ALL = Acute Lymphoblastic Leukemia; APL = Acute promyelocytic leukemia; C = Caucasian; CA = Carcinoma; CML = 
Chronic Myelogenous Leukemia; CNS = Central Nervous System; F = Female; LCIL = Large Cell Immunoblastic Lymphoma; M = Male; MM = 
Multiple Myeloma; NA = Not Available; NSCLC = Non Small Cell Lung Cancer.
The information about the ATCC cell lines (Cell Lines with ATCC no.) was obtained accessing the following URL: http://www.atcc.org. Additional 
information was obtained through the National Cancer Institute's Developmental Therapeutics Program URL: http://dtp.nci.nih.gov/branches/btb/
tumor-catalog.pdf.
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Table 2: Sequence-based typing of NCI-60 HLA class I Loci
Cell Line ID Tissue A locus B Locus Cw Locus
BT-549 41292-D Breast CA N.R. 151701, 5501 030301, 07a
HS 578T 41293-D Breast CA 03a, 24a 35a, 40a 030401, 04a
MCF7 41294-D Breast CA 020101 18a, 44a 05a
MDA-MB-231 41296-D Breast CA 0201, 0217 4002, 4101 020202, 17a
MDA-MB435 41297-D Breast CA 110101, 240201 15a, 35a 030301, 04a
T47D 41298-D Breast CA 3301 1402 0802
SF-268 41286-D CNS CA 010101, 3201 0801, 4002 020202, 07a
SF-295 41287-D CNS CA 010101, 2601 070201, 5501 03a, 07a
SF-539 41288-D CNS CA 020101 08a, 35a 04a, 07a
SNB-19 41289-D CNS CA 020101 18a 05a
SNB-75 41290-D CNS CA 020101, 110101 35a, 39a 04a, 120301
U251 41291-D CNS CA 020101 18a 05a
COLO 205 41299-D Colon CA 01a, 02a 07a, 08a 070201, 07a
HCC-2998 41300-D Colon CA 02a, 24a 3701, 400601 04a, 0602
HCT-116 41301-D Colon CA 01a, 02a 18a, 4501 05a, 07a
HCT-15 41302-D Colon CA 02a, 24a 08new, 350101 04a, 07a
HT29 41303-D Colon CA 01a, 24a 35a, 440301 04a
KM12 41304-D Colon CA 02new 70201 70201
SW-620 41305-D Colon CA 02a, 24a 07a, 15a 070201, 07a
MOLT 4 41281-D Leukemia, ALL 010101, 2501 18a, 570101 0602, 120301
CCRF-CEM 41282-D Leukemia, ALL N.R. 08a, 40a 030401, 07a
HL-60 41284-D Leukemia, APL 10101 570101 0602
K-562 41280-D Leukemia, CML 110101, 310102 18a, 40a 03a, N.R.
SR 41285-D Leukemia, LCIL 02a, 03a 3701, 3901 0602, 120301
LOX IMVI 41315-D Melanoma 110101, 2902 070201, 440301 070201, 1601
M 14 41316-D Melanoma 110101, 240201 15a, 35a 030301, 04a
SK-MEL-2 41317-D Melanoma 03a, 26a 35a, 38a 04a, 120301
SK-MEL-5 41319-D Melanoma 020101, 110101 07a, 40a 030401, 070201
SK-MEL-28 41318-D Melanoma 110101 4001 030401
UACC-62 41321-D Melanoma 02a, 32a 39a, 44a 05a, 12a
UACC-257 41320-D Melanoma 020101 18a, 44a 05a, 07a
RPMI-8226 41283-D MM 3001, 6802 1503, 1510 020204, 030402
A549/ATCC 41306-D NSCLC 2501, 3001 18a, 440301 120301, 1601
EKVX 41307-D NSCLC 010101 3701 0602
HOP-62 41308-D NSCLC 030101 07a, 44a 05a, 070201
HOP-92 41309-D NSCLC 03a, 24a 27a, 470101 01a, 06a
NCI-H23 41312-D NSCLC 8001 5001 0602
NCI-H226 41311-D NSCLC 010101, 240201 07a, 39a 070201, 120301
NCI-H322M 41310-D NSCLC 2902 440301 1601
NCI-H460 41313-D NSCLC 24a, 68a 35a, 51a 03a, 15a
NCI-H522 41314-D NSCLC 020101 44a, 5501 030301, 05a
IGROV1 41322-D Ovarian CA 240201, 3301 4901 07a
OVCAR-3 41323-D Ovarian CA 020101, 2902 070201, 5801 070201, 07a
OVCAR-4 41324-D Ovarian CA 010101, 3201 0801, 4002 07a, 15a
OVCAR-5 41325-D Ovarian CA 01a, 02a 08a, 44a 05a, 07a
OVCAR-8 41326-D Ovarian CA 010101, 2501 570101 0602
NCI/ADR-RES 41295-D Ovarian CA 010101, 2501 570101 0602
SK-OV-3 41327-D Ovarian CA 03a, 68a 18a, 35a 04a, 05a
DU-145 41328-D Prostate CA 030101, 3303 5001, 570101 0602
PC-3 41329-D Prostate CA 010101, 240201 1302, 5501 01a, 06a
786-O 41330-D Renal CA 030101 07a, 44a 05a, 070201
A498 41331-D Renal CA 020101 0801 07aJournal of Translational Medicine 2005, 3:11 http://www.translational-medicine.com/content/3/1/11
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haplotype that we originally described for melanoma cell
lines generated at the National Cancer Institute (Bethesda,
MD) [38,39] and subsequently observed in other cancers
[40,41]. We conclude that this is an unlikely
representative of patients' homozygosity because com-
plete HLA class I and II homozygosity is exceedingly rare
in the population at large. To corroborate this statement,
we analyzed 554 genomic DNA specimens from normal
donors recently typed with the same technology in our
laboratory. Genomic DNA for the normal donors was
obtained from whole blood samples. Only 5 individuals
were found to be truly homozygous for all HLA class I and
class II loci for a frequency of 0.9%.
Overall, discrepancies between ATCC typings and the
present typing or the unbalanced frequency of homozy-
gosity could be related to accumulated genetic alterations
between the cell lines since the time of their original
expansion from the patient and should not be surprising.
A particular case was represented by the NCI/ADR-RES
cell line which was previously believed to be an adriamy-
cin derivative of the breast cancer cell line MCF-7. Subse-
quently, it was discovered not to be related to MCF-7, but
it's derivation was unclear [42]. Karyotyping analysis sug-
gested it was related to the ovarian cell line OVCAR-8.
Subsequent DNA fingerprinting confirmed that both cell
lines were generated from the same individual. HLA gen-
otyping confirms this since the cell lines are indeed
identical.
To avoid possible misinterpretations, a large number of
alleles are not presented here with their definitive nomen-
clature but rather at a two digits level of resolution
because some of the ambiguities could not be completely
resolved by SBT as previously described [43]. However,
more detailed information about individual cell lines can
be obtained by contacting Sharon Adams directly at the
HLA laboratory, Department of Transfusion Medicine,
Bethesda, MD. As previously described [43], it is possible
to resolve most of these ambiguities using various meth-
ods including sequence-specific primer PCR or pyro-
sequencing [44]. If necessary in the future, the NIH HLA
laboratory may assist in further characterization of indi-
vidual HLA alleles. Another caveat is that the identifica-
tion of HLA alleles at the genomic level does not
necessarily correspond to surface expression of their pro-
tein products since various abnormalities in transcription,
translation and assembling could influence the surface
expression of HLA molecules [39,45,46].
Finally, several new alleles were identified (referred to in
the tables as new, for which a nomenclature is pending; in
detail KM12 HLA-A*02new = Genebank Accession #
AY918166; SN12C HLA-A*24new = # AY918167; CAKI-1
HLA-Cw04new = # AY918170). Information regarding
the sequence of these alleles could be obtained by directly
contacting the HLA laboratory, Department of Transfu-
sion Medicine, Bethesda, MD.
Materials and Methods
Cell Lines
Genomic DNA from the NCI-60 cell line anticancer drug
discovery panel was obtained from SH of the National
Cancer Institute Developmental Therapeutics Program
(Bethesda, MD). Cells were grown in RPMI 1640 supple-
mented with 10% fetal bovine serum and 5 mM L-
glutamine.
DNA Isolation
Genomic DNA was isolated from peripheral blood using
the Gentra PUREGENE isolation kit (Gentra Systems,
Minneapolis, MN, USA). The DNA was re-suspended in
Tris HCl buffer (pH 8.5) and the concentration was meas-
ured using a Pharmacia Gene Quant II Spectrophotome-
ter. The DNA was then stored at -70°C until testing.
Sequence-Based Typing (SBT)
HLA class I loci sequence-based typing (SBT) was per-
formed as previously described ([43]. The primary PCR
amplification reaction produced a 1.5 kb amplicon
encompassing exon 1 through intron 3 of the HLA class I
locus. All reagents necessary for primary amplification
and sequencing were included in the HLA-A, HLA-B and
ACHN 41332-D Renal CA 2601 4901 07a
CAKI-1 41333-D Renal CA 2301, 240201 3502, 440301 04a, 04new
SN12C 41334-D Renal CA 03, 24new 07a, 44a 05a, 070201
TK-10 41335-D Renal CA 3301 1402 0802
UO-31 41336-D Renal CA 010101, 030101 07a, 14a 07a, 08a
RXF-393 41337-D Renal CA 02a, 24a 1401, 44a 05a, 0802
Sequence-based typing for the HLA class I loci are reported with the highest degree of resolution. Non-resolved ambiguities are reported as two 
digit denominations with a superscript a as previously described 43. HLA typings divergent from those originally described in the ATCC database 
are reported in red. ID# refers to the HLA laboratory reference number. New alleles are indicated by the suffix new following the allele. N.R. – 
Ambiguity not resolved at the lower level of resolution.
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Table 3: Sequence-based typing of NCI-60 HLA class II Loci
Cell Line ID Tissue DRβ 1 Locus DQB1 Locus DPB1 Locus
BT-549 41292-D Breast CA 11a, 13a 030101, 060401 020102, 0401
HS 578T 41293-D Breast CA 01a, 150101 050101, 0602 0401, 7801
MCF7 41294-D Breast CA 03a, 15a 0201, 0602 020102, 0401
MDA-MB-231 41296-D Breast CA 0701, 1305 0202, 030101 020102, 1701
MDA-MB435 41297-D Breast CA 040501, 130101 0302, 0603 1301, 1901
T47D 41298-D Breast CA 010201 050101 020102, 0401
SF-268 41286-D CNS CA 03a, 04a 0201, 0302 0401, 0601
SF-295 41287-D CNS CA 14a, 15a 050301, 0602 0401
SF-539 41288-D CNS CA 030101, 12a 0201, 030101 010101, 0401
SNB-19 41289-D CNS CA 030101 0201 0402
SNB-75 41290-D CNS CA 0103, 11a 03a, 050101 0401, 0402
U251 41291-D CNS CA 030101 0201 0402
COLO 205 41299-D Colon CA 040101, 130101 0603 0401
HCC-2998 41300-D Colon CA 11a, 16a 030101, 050201 0401
HCT-116 41301-D Colon CA N.R. 02new, 03new 030101, 0402
HCT-15 41302-D Colon CA 03a, 14a 02a, 050301 010101, 0401
HT29 41303-D Colon CA 0402, 0701 02a, 0302 0401
KM12 41304-D Colon CA 040101 0302 1301
SW-620 41305-D Colon CA 0103, 130101 050101, 0603 010101, 0401
MOLT 4 41281-D Leukemia, ALL 07new, 12new 0202, 030101 20102
CCRF-CEM 41282-D Leukemia, ALL 030101, 0701 0201, 0202 0401, 1301
HL-60 41284-D Leukemia, APL N.R. 030302 0401, 1301
K-562 41280-D Leukemia, CML 03a, 04a 0201, 0302 0401, 0402
SR 41285-D Leukemia, LCIL 01a, 160101 050101, 050201 0401
LOX IMVI 41315-D Melanoma 0701, 150101 0202, 0602 0401, 110101
M 14 41316-D Melanoma 040501, 130101 0302, 0603 1301, 1901
SK-MEL-2 41317-D Melanoma 0402, 130101 030101, 0603 020102, 0401
SK-MEL-5 41319-D Melanoma 040101, 130101 0302, 0603 030101, 1601
SK-MEL-28 41318-D Melanoma 0404 0302 030101
UACC-62 41321-D Melanoma 12a, 130101 030101, 0603 0401, 1401
UACC-257 41320-D Melanoma 040101 030101, 0302 0401
RPMI-8226 41283-D MM 030101, 0701 0201, 0202 010102, 1301
A549/ATCC 41306-D NSCLC 0701, 110401 0202, 030101 N.R.
EKVX 41307-D NSCLC 150101 0602 0401
HOP-62 41308-D NSCLC 13a, 15a 06a, 06a 0402
HOP-92 41309-D NSCLC 01a, 150101 050101, 0602 0401, 0402
NCI-H23 41312-D NSCLC 130101 0603 1901
NCI-H226 41311-D NSCLC 150101, 160101 050201, 0602 020102, 0401
NCI-H322M 41310-D NSCLC 0701 0202 0401
NCI-H460 41313-D NSCLC 01a, 04a 030101, 050101 N.R.
NCI-H522 41314-D NSCLC 040101, 150101 03a, 0602 0401
IGROV1 41322-D Ovarian CA 11a, 11a 03new new, 0501
OVCAR-3 41323-D Ovarian CA 080101, 080401 0402 020102, 0401
OVCAR-4 41324-D Ovarian CA 030101, 040101 0201, 030101 0401, 1301
OVCAR-5 41325-D Ovarian CA 030101, 040101 0201, 030101 0401
OVCAR-8 41326-D Ovarian CA 0701, 150101 030302, 0602 020102, 1301
NCI/ADR-RES 41295-D Ovarian CA 0701, 150101 030302, 0602 020102, 1301
SK-OV-3 41327-D Ovarian CA 01a, 030101 0201, 050101 020102, 0401
DU-145 41328-D Prostate CA N.R. 030302, 050101 0401
PC-3 41329-D Prostate CA 0701, 130101 0202, 0603 0401Journal of Translational Medicine 2005, 3:11 http://www.translational-medicine.com/content/3/1/11
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HLA-C alleleSEQR Sequenced Based Typing Kits (Atria
Genetics, Hayward, CA, U.S.A.). The primary amplifica-
tion PCR products were purified from excess primers,
dNTPs and genomic DNA using ExoSAP-IT (American Life
Science, Cleveland, OH, U.S.A.). Each template was
sequenced in the forward and reverse sequence orienta-
tion for exon 2 and exon 3 according to protocols sup-
plied with the SBT kits. Excess dye terminators were
removed from the sequencing products utilizing an etha-
nol precipitation method with absolute ethanol. The reac-
tion products were reconstituted with 15 µl of Hi-Di™
Formamide (PE Applied Biosystems / Perkin-Elmer, Fos-
ter City, CA, U.S.A.) and analyzed on the ABI Prism* 3700
DNA Analyzer with Dye Set file: Z and mobility file:
DT3700POP6 [ET].
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